Mumbai, Maharashtra, India, October 2025 – Sekhmet Pharmaventures Pvt. Ltd., the Indian arm of Singapore-based Gamot API Pte Ltd., has announced the appointment of Mukesh Agarwal as its new Chief Financial Officer (CFO). With more than two decades of leadership experience in finance across the pharmaceutical industry, Mukesh brings deep expertise in financial strategy, governance, risk management, and business performance enhancement spanning the pharma value chain.
Mukesh Agarwal has built a distinguished career in finance, serving in senior leadership roles across several major pharmaceutical organizations in India.
Most recently, he served as Chief Financial Officer at Macleods Pharmaceuticals Ltd., where he led the company’s finance and accounting operations, driving financial governance, cost optimization, and long-term strategic growth. Before becoming CFO, he held the role of Vice President – Finance & Accounts at the same company for around three years, contributing significantly to strengthening Macleods’ financial management framework during its expansion phase.
Prior to this, Mukesh was the Chief Financial Officer at ZCL Chemicals Ltd. (now part of Cohance Lifesciences Ltd.), where he oversaw corporate finance, investor relations, and strategic financial restructuring initiatives. His leadership played a crucial role in supporting ZCL’s transition under new ownership and its growth in specialty chemicals and APIs.
Earlier in his career, Mukesh spent nearly six years with Cipla Ltd. as Director – Finance, leading financial planning for the company’s Global API and R&D verticals, managing commercial contracts across CRO, CDMO, and CMO partnerships. He drove profitability initiatives through portfolio rationalization, working capital optimization, and M&A collaboration, establishing himself as a key strategic partner to the business.
Mukesh also held leadership positions at Plethico Pharmaceuticals, Wockhardt Ltd., and Ipca Laboratories, where he handled diverse responsibilities including global consolidation, audit compliance, and financial restructuring for subsidiaries across Europe and the United States. His early career with Defiance Knitting Industries Pvt. Ltd. marked the beginning of his journey in accounting and finance, laying a strong foundation for his later leadership roles.
About Sekhmet Pharmaventures Pvt. Ltd.
Sekhmet Pharmaventures Pvt. Ltd. is part of Gamot API Pte Ltd., a Singapore-based pharmaceutical investment platform formed by PAG, one of Asia’s leading private equity firms, along with CX Partners and Samara Capital. The platform focuses on acquiring and scaling fast-growing pharmaceutical companies across India’s API and formulation manufacturing sectors.
Sekhmet made its first major investment by acquiring a controlling stake in Anjan Drug Pvt. Ltd. in October 2020, followed by a second investment in the Optimus Drugs Group of Companies in 2022. With India’s growing significance in the global pharmaceutical supply chain, Sekhmet is positioned to play a pivotal role in expanding manufacturing capabilities and supporting innovation-driven growth within the industry.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
